scholarly journals Short-Term Daily Intake of Polydextrose Fiber Does Not Shorten Intestinal Transit Time in Constipated Adults: A Randomized Controlled Trial

Nutrients ◽  
2018 ◽  
Vol 10 (7) ◽  
pp. 920 ◽  
Author(s):  
Peter Duncan ◽  
Catherine Enters-Weijnen ◽  
Nashmil Emami ◽  
Peter McLean ◽  
Tiago Nunes ◽  
...  
Keyword(s):  
Transit Time ◽  
Controlled Trial ◽  
Daily Intake ◽  
Intestinal Transit ◽  
Double Blind ◽  
Intestinal Transit Time ◽  
Gi Symptoms ◽  
Marker Distribution ◽  
Clinical Measures ◽  
In Transit

Chronic constipation (CC) remains a common gastrointestinal (GI) disorder that conveys a substantial healthcare burden. Expert guidelines recommend increasing fiber intake, yet the clinical evidence to support this needs strengthening for specific fibers. The aim was to evaluate changes in intestinal transit time and GI symptoms in CC patients who consumed polydextrose. In a randomized, double-blind, placebo-controlled trial, 128 adults with CC received 8 g or 12 g polydextrose, or placebo, daily for 4 weeks. Transit time, as primary outcome, was assessed by radiopaque marker distribution after 2-weeks intervention. Bowel habits, GI symptoms and quality of life (QOL) were assessed by questionnaire, including the Patient-Assessment of Constipation (PAC) Symptoms (SYM), and PAC-QOL. Following 2-weeks intervention, no reduction was seen in transit time in any group and following 2- or 4-weeks intervention, no improvements were seen in stool frequency or consistency in any group. After 2-weeks intervention with 8 g/day polydextrose an improvement was seen in the PAC-SYM rectal score (p = 0.041). After 4-weeks intervention both rectal (p = 0.049) and stool (p = 0.029) scores improved while improvement in the QOL satisfaction score did not reach significance (p = 0.071). Overall, the results suggest that 2-weeks consumption of 8 or 12 g/day polydextrose does not significantly improve physiological measures of gut function in CC adults. Longer term consumption may improve clinical measures, but further studies will be required to substantiate this.

scholarly journals A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy

Nutrients ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 3171
Author(s):  
Eric Guillemard ◽  
Marion Poirel ◽  
Florent Schäfer ◽  
Laurent Quinquis ◽  
Caroline Rossoni ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gut Microbiota ◽  
Beta Diversity ◽  
Pathogenic Bacteria ◽  
Controlled Trial ◽  
Eradication Therapy ◽  
Fermented Milk ◽  
Control Group ◽  
Double Blind ◽  
Gi Symptoms

Helicobacter pylori (Hp) eradication therapy alters gut microbiota, provoking gastrointestinal (GI) symptoms that could be improved by probiotics. The study aim was to assess the effect in Hp patients of a Test fermented milk containing yogurt and Lacticaseibacillus (L. paracasei CNCM I-1518 and I-3689, L. rhamnosus CNCM I-3690) strains on antibiotic associated diarrhea (AAD) (primary aim), GI-symptoms, gut microbiota, and metabolites. A randomised, double-blind, controlled trial was performed on 136 adults under 14-day Hp treatment, receiving the Test or Control product for 28 days. AAD and GI-symptoms were reported and feces analysed for relative and quantitative gut microbiome composition, short chain fatty acids (SCFA), and calprotectin concentrations, and viability of ingested strains. No effect of Test product was observed on AAD or GI-symptoms. Hp treatment induced a significant alteration in bacterial and fungal composition, a decrease of bacterial count and alpha-diversity, an increase of Candida and calprotectin, and a decrease of SCFA concentrations. Following Hp treatment, in the Test as compared to Control group, intra-subject beta-diversity distance from baseline was lower (padj = 0.02), some Enterobacteriaceae, including Escherichia-Shigella (padj = 0.0082) and Klebsiella (padj = 0.013), were less abundant, and concentrations of major SCFA (p = 0.035) and valerate (p = 0.045) were higher. Viable Lacticaseibacillus strains were detected during product consumption in feces. Results suggest that, in patients under Hp treatment, the consumption of a multi-strain fermented milk can induce a modest but significant faster recovery of the microbiota composition (beta-diversity) and of SCFA production and limit the increase of potentially pathogenic bacteria.

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial*

1996 ◽  
Vol 59 (4) ◽  
pp. 469-475 ◽  
Author(s):  
Chun-Su Yuan ◽  
Joseph F. Foss ◽  
Michael O'Connor ◽  
Alicia Toledano ◽  
Michael F. Roizen ◽  
...  
Keyword(s):  
Transit Time ◽  
Controlled Trial ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document